Deschloroketamine (DCK, 2'-oxo-PCM, O-PCM) is a synthetic dissociative anesthetic of the arylcyclohexylamine class, structurally identical to ketamine except for the absence of the chlorine atom at the 2-position of the phenyl ring. This seemingly modest structural change produces meaningful pharmacological differences: DCK is significantly more potent than ketamine by weight, has a substantially longer duration of action (3–4 hours compared to ketamine's 1–1.5 hours), and is described by community members as producing a somewhat different qualitative experience — deeper, more introspective, and less "floaty" than ketamine.
DCK was among the earliest ketamine analogs to emerge as a research chemical and established much of the community harm reduction framework that would later be applied to other ketamine analogs like 2-FDCK. Community experience is substantial: users describe DCK as offering a "deeper" hole than ketamine at comparable subjective intensities, with a more pronounced cognitive impact and longer recovery time. A community thread specifically addressed and corrected misinformation about DCK's legal status in China, reflecting the active community engagement around this substance.
The primary harm reduction concerns for DCK mirror those for ketamine: bladder toxicity with frequent use, psychological dependence, and the risk of CNS depression in combination with sedatives. The longer duration compared to ketamine means that the window of impairment and risk exposure is extended, and redosing mistakes are more consequential.
Safety at a Glance
High Risk- Adjust for Potency — DCK is Not Ketamine
- Bladder Protection is Paramount
- Toxicity: Bladder and Urological Toxicity As with ketamine, regular use of DCK carries significant risk of bladder and urinary ...
- Dangerous with: Acetylfentanyl, Buprenorphine, Codeine, Desomorphine (+15 more)
- Overdose risk: Overdose on Deschloroketamine can range from unpleasant to life-threatening depending on the dose...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
insufflated
oral
smoked
Duration
insufflated
Total: 3 hrs – 6 hrsoral
Total: 4 hrs – 6 hrssmoked
Total: 30 min – 1.5 hrsHow It Feels
The first signs are familiar to anyone who knows ketamine: a gentle numbing in the extremities, a softening of sound, and a subtle shift in the way the room occupies space. But where ketamine rushes in like a tide, Deschloroketamine takes its time. The onset unfolds over thirty to forty-five minutes, each stage arriving with an almost deliberate patience, as though the compound is carefully adjusting each parameter of consciousness one by one, making sure each setting is correct before moving to the next.
The come-up builds a dissociation that is cleaner and less wobbly than ketamine's — there is a clarity here, a transparency to the altered state that allows you to observe it even as it deepens. Sound takes on that characteristic dissociative reverb, as though the room has expanded to twice its actual size, but the effect is precise rather than muddy. Music becomes three-dimensional, each instrument occupying a specific location in a vast internal space. The body grows pleasantly numb and weightless; the usual aches and tensions of physical existence are gently erased, replaced by a floating neutrality that is deeply comfortable without being euphoric.
At the peak, which may arrive an hour or more after ingestion, the dissociation reaches a depth that is genuinely ketamine-like but more architecturally coherent. Closed-eye space opens into vast geometric landscapes — not chaotic or overwhelming, but ordered, as though designed by a mathematician with a keen aesthetic sense. Tunnels, lattices, crystalline caverns that extend in all directions, rendered in cool blues and silvers. You can navigate these spaces with your attention, moving through them with a dream-like agency. The sense of self thins to a fine filament but rarely breaks entirely — you remain a point of awareness moving through an abstract landscape, whereas ketamine might dissolve that point entirely. The emotional register is contemplative and serene.
The duration is notably longer than ketamine — the plateau can hold for three to four hours, and full return to baseline may take six or seven. The descent is gradual and smooth, the geometric spaces slowly losing resolution, the body slowly regaining its weight and boundaries. There is a gentle afterglow of mental quiet that can last into the following day, a residual sense that the noise floor of consciousness has been temporarily lowered. Sleep comes easily but may be unusually vivid, populated by the same geometric motifs that characterized the experience itself.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(15)
- Decreased libido— Decreased libido is a diminished interest in and desire for sexual activity, commonly caused by subs...
- Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
- Muscle relaxation— The experience of muscles throughout the body losing their rigidity and tension, becoming noticeably...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Orgasm suppression— Orgasm suppression (anorgasmia) is the difficulty or complete inability to achieve orgasm despite ad...
- Pain relief— A suppression of negative physical sensations such as aches and pains, ranging from dulled awareness...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical autonomy— Physical autonomy is the experience of one's body performing actions — from simple tasks like walkin...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Spatial disorientation— Spatial disorientation is the inability to accurately perceive one's position or orientation within ...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Tactile(1)
- Tactile suppression— A progressive decrease in the ability to feel physical touch, ranging from mild numbness to complete...
Cognitive & Perceptual Effects
Visual(11)
- Double vision— The visual experience of seeing a single object as two separate, overlapping images, similar to cros...
- Environmental cubism— A visual distortion in which the environment and objects within it appear fragmented into geometric,...
- Frame rate suppression— Perception of visual motion as choppy discrete frames rather than smooth continuous flow, resembling...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Visual acuity suppression— Vision becomes blurred, indistinct, and out of focus, as though looking through a smudged lens. Fine...
- Visual disconnection— A dissociative visual effect involving a progressive detachment from visual perception, ranging from...
Cognitive(20)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Analysis suppression— Analysis suppression is a cognitive impairment in which the capacity for logical reasoning, critical...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Creativity enhancement— An increase in the ability to imagine new ideas, overcome creative blocks, think about existing conc...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Depersonalization— A detachment from one's own sense of self, body, or mental processes, as if observing oneself from o...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Derealization— A perceptual disturbance in which the external world feels profoundly unreal, dreamlike, or artifici...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Dream potentiation— Enhanced dream vividness, complexity, and recall, often occurring as REM rebound after discontinuing...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
Multi-sensory(2)
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
- Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(3)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
DCK acts as a non-competitive NMDA receptor antagonist through the same open-channel blocking mechanism as ketamine and other arylcyclohexylamines. Binding studies suggest DCK has similar or slightly higher affinity for the NMDA receptor channel than ketamine, consistent with its greater potency by weight.
Structural Comparison to Ketamine
The sole structural difference from ketamine is the absence of the 2-chloro substituent on the phenyl ring. This change affects:
- Lipophilicity — the dechlorinated compound has altered membrane penetration kinetics
- Metabolic handling — different cytochrome P450 processing yields different metabolites and pharmacokinetics
- Duration — the net effect is a significantly longer duration, typically 3–4 hours vs 1–1.5 hours for ketamine at equivalent effect intensities
Serotonin Reuptake Inhibition
Like ketamine, DCK is believed to have some serotonin reuptake inhibitory activity, contributing to mood effects and potentially some of the experiential differences from pure NMDA antagonists.
Potency
Community experience consistently indicates DCK is significantly more potent than ketamine. Users transitioning from ketamine to DCK who apply ketamine dosing conventions routinely report over-shooting. Dose references suggest DCK is approximately 2–3x more potent than ketamine by weight, though individual variation is substantial.
Tolerance
Tolerance develops with repeated use, and cross-tolerance with other NMDA antagonists (ketamine, 2-FDCK, MXE) is expected. Psychological dependence with compulsive use patterns is documented in community experience.
Detection Methods
Standard Drug Panel Inclusion
Deschloroketamine (DCK, 2-oxo-PCM) is NOT included on standard drug screening panels. Ketamine is not on standard 5-panel or 10-panel tests, and DCK, which lacks the chlorine atom present in ketamine, is even less likely to cross-react with any ketamine-specific immunoassay. Standard screening will produce negative results.
Urine Detection
DCK is detectable in urine for approximately 2 to 5 days after a single dose. The compound is metabolized by N-demethylation and hydroxylation, producing metabolites structurally analogous to norketamine but without the chlorine atom. The longer duration of action reported for DCK compared to ketamine (4 to 6 hours versus 1 to 2 hours) suggests greater metabolic stability, which may extend the detection window. LC-MS/MS methods specifically targeting DCK and its metabolites are required.
Blood and Serum Detection
Blood detection windows are approximately 1 to 3 days. The extended duration of action suggests slower clearance from blood compared to ketamine. Pharmacokinetic data comes primarily from case reports and in vitro studies.
Hair Follicle Detection
Hair analysis is feasible with LC-MS/MS methods. The compound's lipophilicity is expected to support incorporation into the hair matrix, with detection windows up to 90 days.
Confirmatory Methods
LC-MS/MS provides definitive identification. The absence of the chlorine atom means the characteristic chlorine isotope pattern seen in ketamine mass spectra will be absent, providing a clear analytical distinction. GC-MS is also applicable with appropriate reference standards.
Reagent Testing
The Marquis reagent produces no reaction with DCK. The Mandelin reagent may produce a faint orange to brown color. The Morris reagent produces a characteristic color change with arylcyclohexanone compounds. Fentanyl test strips should be used on all products from unregulated sources.
Interactions
| Substance | Status | Note |
|---|---|---|
| Acetylfentanyl | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Buprenorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Codeine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Desomorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Dextropropoxyphene | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Dihydrocodeine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Ethylmorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Fentanyl | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Heroin | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Hydrocodone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Hydromorphone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Kratom | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Methadone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Morphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Naloxone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| O-Desmethyltramadol | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Oxycodone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Oxymorphone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Pethidine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| 1,4-Butanediol | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 2-Fluorodeschloroketamine | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 2M2B | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 3-Cl-PCP | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-HO-PCE | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 1,3-Butanediol | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1B-LSD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-AL-LAD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-LSD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-MiPLA | Low Risk & Synergy | Produces unique synergistic effects; often combined |
History
Development
Deschloroketamine was synthesized as part of the broader exploration of ketamine structural analogs — a research tradition extending back to the original SAR studies of arylcyclohexylamines in the 1960s and 1970s. The removal of ketamine's 2-chloro substituent is a straightforward structural modification that was explored relatively early in this research context.
Emergence as a Research Chemical
DCK became available as a research chemical in the early-to-mid 2010s, predating and overlapping with the 2-FDCK era. It established itself as a prominent ketamine substitute in markets where ketamine was unavailable or expensive. Community discussion on forums and social media platforms generated extensive harm reduction guidance during this period.
Legal Status Controversy
Community archives contain a specific thread correcting misinformation about DCK's legal status in China — reflecting the complex and rapidly evolving legal landscape for novel dissociatives and the importance of accurate information for harm reduction purposes. DCK's legal status varies by jurisdiction and has changed over time as regulators have moved to schedule novel ketamine analogs explicitly.
Role in Dissociative Community History
DCK played an important role in the evolution of community harm reduction around novel dissociatives, serving as a case study for how longer duration and greater potency require specific adjustments to dosing frameworks developed for ketamine. The harm reduction lessons from the DCK community were applied to later compounds including 2-FDCK.
Harm Reduction
Adjust for Potency — DCK is Not Ketamine
The most critical practical harm reduction point: DCK is approximately 2–3x more potent than ketamine by weight. If you are transitioning from ketamine, dramatically reduce your starting dose. Begin with 1/3 of your typical ketamine dose, assess fully over the longer 3–4 hour duration, then adjust.
Bladder Protection is Paramount
DCK carries the same bladder toxicity risk as ketamine. Community harm reduction consensus:
- Use no more than once per week; ideally once per month or less
- Stay hydrated before and after use
- Monitor for urological symptoms; cease immediately if they appear
- Early-stage bladder damage from ketamine-class compounds is reversible with abstinence
Respect the Duration
The 3–4 hour duration (vs ketamine's 1–1.5 hours) is not just a matter of extended enjoyment — it extends the window of vulnerability. Ensure you have 5–6 hours with nothing requiring your function. Do not plan activities, driving, or responsibilities within 6 hours of dosing.
Redosing Strategy
Do not redose until a minimum of 2 hours after the initial dose, and only if the initial dose has clearly peaked and begun to decline. Premature redosing with DCK is a common cause of unexpectedly intense experiences.
Set Up Safely
As with all potent dissociatives:
- Use lying down in a secure environment where falling is not possible
- Have no hazardous objects in reach
- Ideally have a sober companion for deeper explorations
Toxicity & Safety
Bladder and Urological Toxicity
As with ketamine, regular use of DCK carries significant risk of bladder and urinary tract toxicity. The mechanism — involving metabolites that damage the uroepithelium — is expected to apply to DCK based on structural similarity. The extended duration of DCK compared to ketamine means that per-session exposure duration is longer, potentially amplifying this risk.
Warning signs: painful urination, urgency, frequency, blood in urine, reduced bladder capacity. These symptoms require immediate cessation and medical evaluation.
Psychological Dependence
DCK's longer duration and potency create conditions for psychological dependence. Community accounts describe "chasing the hole" patterns with DCK as a recognized hazard. The more profound cognitive impact described by experienced users appears to be both an attractive feature and a dependence risk factor.
Cognitive Effects with Chronic Use
As with ketamine, heavy or chronic use of DCK may produce lasting cognitive effects — deficits in memory, executive function, and processing speed. These appear to be at least partially reversible with abstinence.
Respiratory Depression
At extreme doses or in combination with CNS depressants, respiratory depression can occur. DCK alone at recreational doses does not typically produce clinically significant respiratory compromise, but combination with opioids, alcohol, or benzodiazepines increases this risk meaningfully.
Cardiovascular Effects
Mild to moderate cardiovascular stimulation (elevated heart rate, blood pressure) occurs as with ketamine. Generally well-tolerated in healthy individuals.
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
Overdose on Deschloroketamine can range from unpleasant to life-threatening depending on the dose, route, and whether other substances are involved.
Signs of overdose: Severe nystagmus, complete unresponsiveness, vomiting (aspiration risk while unconscious), severely depressed breathing, seizures, extremely elevated heart rate or blood pressure.
Critical dangers:
- Respiratory depression: Particularly when combined with other depressants
- Aspiration: Loss of protective reflexes combined with nausea creates choking risk
- Hyperthermia or hypothermia: Impaired thermoregulation at high doses
Emergency response: Place the person in the recovery position. Monitor breathing. Call emergency services if breathing is slow, shallow, or irregular; if the person is unresponsive to stimulation; or if seizures occur. Be honest with medical personnel about what was consumed — they are there to help, not to judge.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Italy:** Deschloroketamine is illegal in Italy.
Latvia:** Deschloroketamine is illegal in Latvia.
Germany:** Deschloroketamine is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Switzerland:** Deschloroketamine is a controlled substance specifically named under Verzeichnis E.
United Kingdom:** Deschloroketamine is a class B drug in the UK and is illegal to possess, produce, supply, or import. As an N-alkyl derivative of 2-Amino-2-phenylcyclohexanone, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.
Czech Republic:** Deschloroketamine is legal in the Czech Republic.
Austria:** Deschloroketamine is illegal in Austria under the NPSV (Neue-Psychoaktive-Substanzen-Verordnung).
Netherlands:** Deschloroketamine can be legally bought as it is not covered by the 1st of July 2025 'blanket ban' Nieuwe Psychoactieve Stoffen (NPS).
Responsible use
Designer drug
Dissociative
=External links=
Deschloroketamine (Wikipedia)
Deschloroketamine (Isomer Design)
Discussion
The Big & Dandy Deschloroketamine Thread (Bluelight)
Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
Experience Reports (1)
Tips (7)
If insufflating Deschloroketamine, start with a small bump and wait 15-20 minutes to assess effects before taking more. Onset via insufflation is faster than oral, but full effects still take time to manifest.
Tolerance to Deschloroketamine builds with regular use. Taking breaks of at least 1-2 weeks between sessions helps prevent tolerance escalation and reduces the risk of bladder and cognitive damage from frequent use.
DCK's longer duration increases the risk of compulsive redosing — you may feel like the peak has passed when you're actually still well within the active window. Set a firm rule not to redose within 3 hours. Frequent use of any arylcyclohexylamine can cause bladder and urinary tract damage.
Common doses of DCK are 10-30mg insufflated. It is more potent by weight than ketamine. Start with 5-10mg to assess your batch's potency, as quality and purity vary significantly between sources.
Do not combine Deschloroketamine with other CNS depressants (alcohol, opioids, benzodiazepines). Dissociatives already depress breathing and cardiovascular function. Adding other depressants creates dangerous respiratory depression.
Deschloroketamine (DCK/DXE) is a dissociative with a notably longer duration than ketamine — effects can last 4-6 hours compared to ketamine's 1-2 hours. Plan accordingly and don't redose too quickly thinking it isn't working.
Community Discussions (1)
See Also
References (4)
- Ketamine as a rapid antidepressant — Berman et al. Biological Psychiatry (2000)paper
- PubChem: Deschloroketamine
PubChem compound page for Deschloroketamine (CID: 437168)
pubchem - Deschloroketamine - TripSit Factsheet
TripSit factsheet for Deschloroketamine
tripsit - Deschloroketamine - Wikipedia
Wikipedia article on Deschloroketamine
wikipedia